TW202228691A - 醫藥調配物 - Google Patents

醫藥調配物 Download PDF

Info

Publication number
TW202228691A
TW202228691A TW110135559A TW110135559A TW202228691A TW 202228691 A TW202228691 A TW 202228691A TW 110135559 A TW110135559 A TW 110135559A TW 110135559 A TW110135559 A TW 110135559A TW 202228691 A TW202228691 A TW 202228691A
Authority
TW
Taiwan
Prior art keywords
child
amount
individual
mitapaiva
pharmaceutically acceptable
Prior art date
Application number
TW110135559A
Other languages
English (en)
Chinese (zh)
Inventor
梁綽睿
艾瑞克 席蒙
印綺平
Original Assignee
美商阿吉歐斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商阿吉歐斯製藥公司 filed Critical 美商阿吉歐斯製藥公司
Publication of TW202228691A publication Critical patent/TW202228691A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110135559A 2020-09-25 2021-09-24 醫藥調配物 TW202228691A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US63/083,834 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US63/107,196 2020-10-29
US202163238483P 2021-08-30 2021-08-30
US63/238,483 2021-08-30

Publications (1)

Publication Number Publication Date
TW202228691A true TW202228691A (zh) 2022-08-01

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110135559A TW202228691A (zh) 2020-09-25 2021-09-24 醫藥調配物

Country Status (10)

Country Link
US (1) US20230338283A1 (https=)
EP (1) EP4216956A1 (https=)
JP (1) JP2023542701A (https=)
KR (1) KR20230074536A (https=)
AU (1) AU2021347349A1 (https=)
CA (1) CA3196829A1 (https=)
IL (1) IL301596A (https=)
MX (1) MX2023003431A (https=)
TW (1) TW202228691A (https=)
WO (1) WO2022067039A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
JP7275130B2 (ja) * 2017-11-22 2023-05-17 アジオス ファーマシューティカルズ， インコーポレイテッド Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Also Published As

Publication number Publication date
US20230338283A1 (en) 2023-10-26
MX2023003431A (es) 2023-05-12
WO2022067039A1 (en) 2022-03-31
CA3196829A1 (en) 2022-03-31
KR20230074536A (ko) 2023-05-30
JP2023542701A (ja) 2023-10-11
IL301596A (en) 2023-05-01
AU2021347349A1 (en) 2023-06-08
EP4216956A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
EP3684333A2 (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
CN120379676A (zh) 治疗阿拉杰里综合征(algs)
US20220323429A1 (en) Pimavanserin for treating neurodegenerative diseases
US20260076986A1 (en) A combination of scyllo-inositol and flavones
TW201022238A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
TW202228691A (zh) 醫藥調配物
WO2006034611A1 (en) Use of lactobacillus plantarum st-iii in losing weight
ES2396011T3 (es) Preparación de enlazantes de fosfato y enlazantes de fosfato preparados de este modo
CN116568281A (zh) 药物制剂
WO2013013195A1 (en) Compositions and methods for treating polycythemia vera and essential thrombocythemia
JP7804698B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤
CN107205991A (zh) 增重化合物的组合物及其长期使用方法
TW202428284A (zh) 向患者提供依考匹泮（ｅｃｏｐｉｐａｍ）療法之方法
US12453729B2 (en) Pharmaceutical formulations
Ross et al. P1498: initial data from the beacon trial: a phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria
US20190247405A1 (en) Treatment of sma
CN117731721B (zh) 植物提取物组合物及其应用
CN116492327B (zh) (2s,6s)-2,6-二氨基庚二酸在制备抗产后抑郁药物中的应用
WO2026053257A1 (en) Method of treating muscular dystrophies
CN102416012A (zh) 一种治疗小儿多动症的药物组合物
KR20240004683A (ko) 알펠리십 제형
EP4539826A1 (en) Novel oral dosage form
WO2024123738A1 (en) Compositions and methods for treating diseases responsive to akg-vitamin b coadministration
CN117771200A (zh) 一种兽用体内外驱虫片剂及其制备方法
CHECK et al. 2.72 Atomoxetine